Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model
Public DepositedAdd to collection
You do not have access to any existing collections. You may create a new collection.
Downloadable Content
Download PDFCitation
MLA
Price, L.S.L, et al. Minibeam Radiation Therapy Enhanced Tumor Delivery of Pegylated Liposomal Doxorubicin In a Triple-negative Breast Cancer Mouse Model. SAGE Publications Inc., 2021. https://doi.org/10.17615/grxz-vy26APA
Price, L., Rivera, J., Madden, A., Herity, L., Piscitelli, J., Mageau, S., Santos, C., Roques, J., Midkiff, B., Feinberg, N., Darr, D., Chang, S., & Zamboni, W. (2021). Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model. SAGE Publications Inc. https://doi.org/10.17615/grxz-vy26Chicago
Price, L.S.L., J.N Rivera, A.J Madden, L.B Herity, J.A Piscitelli, S Mageau, C.M Santos et al. 2021. Minibeam Radiation Therapy Enhanced Tumor Delivery of Pegylated Liposomal Doxorubicin In a Triple-Negative Breast Cancer Mouse Model. SAGE Publications Inc.. https://doi.org/10.17615/grxz-vy26- Creator
-
Price, L.S.L.
- Other Affiliation: Division of Pharmacotherapy Experimental Therapeutics
-
Rivera, J.N.
- Affiliation: School of Medicine, Joint Department of Biomedical Engineering, North Carolina State University
-
Madden, A.J.
- Other Affiliation: Division of Pharmacotherapy Experimental Therapeutics
-
Herity, L.B.
- Other Affiliation: Division of Pharmacotherapy Experimental Therapeutics
-
Piscitelli, J.A.
- Other Affiliation: Division of Pharmacotherapy Experimental Therapeutics
-
Mageau, S.
- Other Affiliation: Division of Pharmacotherapy Experimental Therapeutics
-
Santos, C.M.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Roques, J.R.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Midkiff, B.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Feinberg, N.N.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Darr, D.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Chang, S.X.
- Affiliation: School of Medicine, Joint Department of Biomedical Engineering, North Carolina State University
-
Zamboni, W.C.
- Other Affiliation: Division of Pharmacotherapy Experimental Therapeutics
- Abstract
- Background: Minibeam radiation therapy is an experimental radiation therapy utilizing an array of parallel submillimeter planar X-ray beams. In preclinical studies, minibeam radiation therapy has been shown to eradicate tumors and cause significantly less damage to normal tissue compared to equivalent radiation doses delivered by conventional broadbeam radiation therapy, where radiation dose is uniformly distributed. Methods: Expanding on prior studies that suggested minibeam radiation therapy increased perfusion in tumors, we compared a single fraction of minibeam radiation therapy (peak dose:valley dose of 28 Gy:2.1 Gy and 100 Gy:7.5 Gy) and broadbeam radiation therapy (7 Gy) in their ability to enhance tumor delivery of PEGylated liposomal doxorubicin and alter the tumor microenvironment in a murine tumor model. Plasma and tumor pharmacokinetic studies of PEGylated liposomal doxorubicin and tumor microenvironment profiling were performed in a genetically engineered mouse model of claudin-low triple-negative breast cancer (T11). Results: Minibeam radiation therapy (28 Gy) and broadbeam radiation therapy (7 Gy) increased PEGylated liposomal doxorubicin tumor delivery by 7.1-fold and 2.7-fold, respectively, compared to PEGylated liposomal doxorubicin alone, without altering the plasma disposition. The enhanced tumor delivery of PEGylated liposomal doxorubicin by minibeam radiation therapy is consistent after repeated dosing, is associated with changes in tumor macrophages but not collagen or angiogenesis, and nontoxic to local tissues. Our study indicated that the minibeam radiation therapy’s ability to enhance the drug delivery decreases from 28 to 100 Gy peak dose. Discussion: Our studies suggest that low-dose minibeam radiation therapy is a safe and effective method to significantly enhance the tumor delivery of nanoparticle agents.
- Date of publication
- 2021
- Keyword
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- License
- Attribution-NonCommercial 4.0 International
- Journal title
- Therapeutic Advances in Medical Oncology
- Journal volume
- 13
- Language
- English
- Version
- Publisher
- Funder
- National Institutes of Health, NIH: T32CA196589; National Cancer Institute, NCI: 2-P30-CA016086-40; National Institute of Environmental Health Sciences, NIEHS: 2-P30ES010126-15A1; University of North Carolina, UNC: 5P30CA016086-41; Eshelman Institute for Innovation, University of North Carolina at Chapel Hill: 1U54CA198999-01, RX03512214
- ISSN
- 1758-8340
- Publisher
- SAGE Publications Inc.
Relations
- Parents:
- In Collection:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
17588359211053700.pdf | 2022-02-08 | Public | Download |